title: Lipid lowering: PCSK9 inhibitors - new kids on the block target their breakthrough.
authors.affiliation: Department of Nephrology, Hypertension and Clinical Pharmacology; Department of Clinical Research; both University of Bern, Switzerland.
authors.forename: Markus
authors.initials: M
authors.lastname: Mohaupt
mesh_terms: D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001055:Apolipoproteins B / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism; D050171:Dyslipidemias / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy / Q000235:genetics; D000091362:PCSK9 Inhibitors; D000071449:Proprotein Convertase 9
chemical_list: D000924:Anticholesteremic Agents; D001055:Apolipoproteins B; D008078:Cholesterol, LDL; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9